DK3630847T3 - Adamts-bindende immunglobuliner - Google Patents

Adamts-bindende immunglobuliner Download PDF

Info

Publication number: DK3630847T3
Authority: DK; Denmark
Prior art keywords: immunglobulins; adamts; binding; binding immunglobulins
Prior art date: 2017-06-02

Application number

DK18730689.9T

Other languages

English (en)

Inventor

Marie-Ange Buyse

Guy Hermans

Sven Lindemann

Hans Guehring

Ralf Guenther

Roland Kellner

Original Assignee

Merck Patent Gmbh

Ablynx Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-06-02

Filing date

2018-06-04

Publication date

2024-12-02

2018-06-04 Application filed by Merck Patent Gmbh, Ablynx Nv filed Critical Merck Patent Gmbh

2024-12-02 Application granted granted Critical

2024-12-02 Publication of DK3630847T3 publication Critical patent/DK3630847T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Bipolar Transistors (AREA)

DK18730689.9T 2017-06-02 2018-06-04 Adamts-bindende immunglobuliner DK3630847T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP17174403		2017-06-02
PCT/EP2018/064665 WO2018220234A1 (en)	2017-06-02	2018-06-04	Adamts binding immunoglobulins

Publications (1)

Publication Number	Publication Date
DK3630847T3 true DK3630847T3 (da)	2024-12-02

Family

ID=59014502

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK18730689.9T DK3630847T3 (da)	2017-06-02	2018-06-04	Adamts-bindende immunglobuliner

Country Status (22)

Country	Link
US (3)	US11261260B2 (da)
EP (2)	EP3630847B1 (da)
JP (2)	JP7758459B2 (da)
KR (2)	KR20250011229A (da)
CN (2)	CN118894939A (da)
AU (2)	AU2018277343B2 (da)
BR (1)	BR112019024333A2 (da)
CA (1)	CA3063293A1 (da)
DK (1)	DK3630847T3 (da)
ES (1)	ES3002733T3 (da)
FI (1)	FI3630847T3 (da)
HR (1)	HRP20241562T1 (da)
HU (1)	HUE068952T2 (da)
IL (1)	IL270908B1 (da)
LT (1)	LT3630847T (da)
MX (1)	MX2019014400A (da)
PL (1)	PL3630847T3 (da)
PT (1)	PT3630847T (da)
RS (1)	RS66191B1 (da)
SI (1)	SI3630847T1 (da)
TW (1)	TWI802576B (da)
WO (1)	WO2018220234A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11644471B2 (en)	2010-09-30	2023-05-09	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SG10201805064SA (en)	2011-06-23	2018-07-30	Ablynx Nv	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CN118894939A (zh)	2017-06-02	2024-11-05	默克专利股份有限公司	结合adamts的免疫球蛋白
US20240027467A1 (en) *	2019-12-20	2024-01-25	Vib Vzw	Nanobody Exchange Chromatography
IL308047A (en)	2021-04-30	2023-12-01	Novartis Ag	Methods of administration of IMDs that bind immunoglobulins
US11970548B2 (en) *	2021-08-27	2024-04-30	Innovative Cellular Therapeutics Holdings, Ltd.	Nanobody target GCC and uses in chimeric antigen receptor cell therapy

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB335768A (en)	1929-10-24	1930-10-02	Jacoviac Maurice	Improvements in protecting devices for gramophone disc records
US4938949A (en)	1988-09-12	1990-07-03	University Of New York	Treatment of damaged bone marrow and dosage units therefor
EP0368684B2 (en)	1988-11-11	2004-09-29	Medical Research Council	Cloning immunoglobulin variable domain sequences.
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
SE509359C2 (sv)	1989-08-01	1999-01-18	Cemu Bioteknik Ab	Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
DK1621554T4 (da)	1992-08-21	2012-12-17	Univ Bruxelles	Immunoglobuliner blottet for lette kæder
ES2162863T3 (es)	1993-04-29	2002-01-16	Unilever Nv	Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
ES2155854T3 (es)	1993-06-09	2001-06-01	Unilever Nv	Procedimiento de produccion de proteinas de fusion que comprende fragmentos de scfv con la ayuda de un molde transformado.
FR2708622B1 (fr)	1993-08-02	1997-04-18	Raymond Hamers	Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0739981A1 (en)	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ES2294799T3 (es)	1996-06-27	2008-04-01	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw.	Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
US6329516B1 (en)	1997-04-28	2001-12-11	Fmc Corporation	Lepidopteran GABA-gated chloride channels
DK1027439T3 (da)	1997-10-27	2010-05-10	Bac Ip Bv	Multivalente antigenbindende proteiner
AU3596599A (en)	1998-01-26	1999-08-09	Unilever Plc	Method for producing antibody fragments
KR20010034512A (ko)	1998-02-19	2001-04-25	베렌슨, 론	림프구 활성화 조절을 위한 조성물 및 그 방법
EP0967284A1 (en)	1998-05-28	1999-12-29	Pfizer Limited	Phosphodiesterases
EP1141711A1 (en)	1999-01-05	2001-10-10	Unilever Plc	Binding of antibody fragments to solid supports
DK1144616T4 (da)	1999-01-19	2009-03-30	Unilever Nv	Fremgangsmåde til fremstilling af antistoffragmenter
CA2361678A1 (en)	1999-02-05	2000-08-10	Rijksuniversiteit Leiden	Method of modulating metabolite biosynthesis in recombinant cells
DE60035163T2 (de)	1999-03-15	2008-02-21	University Of British Columbia, Vancouver	Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
CA2370351A1 (en)	1999-04-22	2000-11-02	Unilever Plc	Inhibition of viral infection using monovalent antigen-binding proteins
CN100513570C (zh)	1999-06-18	2009-07-15	Cv治疗公司	结合框运输蛋白abc1的调节作用
IL147920A0 (en)	1999-08-02	2002-08-14	Keygene Nv	Method for generating cgmmv resistant plants, genetic constructs, and the obtained cgmmv-resistant plants
US6391610B1 (en)	1999-08-06	2002-05-21	The Cleveland Clinic Foundation	Nucleic acids encoding zinc metalloproteases
GB9922124D0 (en)	1999-09-17	1999-11-17	Pfizer Ltd	Phosphodiesterase enzymes
US6479280B1 (en)	1999-09-24	2002-11-12	Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw	Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
DE19955408A1 (de)	1999-11-18	2001-05-23	Bayer Ag	GABA-B-Rezeptoren
ES2331051T3 (es)	1999-11-29	2009-12-21	Bac Ip B.V.	Inmovilizacion de moleculas de union de antigenos de un dominio.
WO2001040310A2 (en)	1999-11-29	2001-06-07	Unilever Plc	Immobilisation of proteins using a polypeptide segment
EP1240337B1 (en)	1999-12-24	2006-08-23	Genentech, Inc.	Methods and compositions for prolonging elimination half-times of bioactive compounds
ES2324280T3 (es)	2000-03-14	2009-08-04	Unilever N.V.	Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos.
US20030190598A1 (en)	2000-05-26	2003-10-09	Jasmid Tanha	Single-domain antigen-binding antibody fragments derived from llama antibodies
US20020151702A1 (en)	2000-10-18	2002-10-17	Genetics Institute, Inc.	Aggrecanase molecules
JP2004512043A (ja)	2000-10-20	2004-04-22	ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー	新規アグレカナーゼ分子
AU2002239680A1 (en)	2000-10-27	2002-06-03	Genetics Institute, Llc	Aggrecanase adamts9
ATE513854T1 (de)	2000-12-13	2011-07-15	Bac Ip B V	Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
AU2002335930B2 (en)	2001-03-09	2005-07-28	Morphosys Ag	Serum albumin binding moieties
DK1399484T3 (da)	2001-06-28	2010-11-08	Domantis Ltd	Dobbelt-specifik ligand og anvendelse af denne
US20060073141A1 (en)	2001-06-28	2006-04-06	Domantis Limited	Compositions and methods for treating inflammatory disorders
JP4213586B2 (ja)	2001-09-13	2009-01-21	株式会社抗体研究所	ラクダ抗体ライブラリーの作製方法
US20030105313A1 (en)	2001-10-16	2003-06-05	American Home Products Corporation	Aggrecanase molecules
JP2005289809A (ja)	2001-10-24	2005-10-20	Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw)	突然変異重鎖抗体
EP1456410A2 (en)	2001-12-11	2004-09-15	AlgoNomics N.V.	Method for displaying loops from immunoglobulin domains in different contexts
EP1456237A2 (en)	2001-12-21	2004-09-15	Vlaams Interuniversitair Instituut voor Biotechnologie vzw.	Method for cloning of variable domain sequences
CA2471645A1 (en)	2002-01-03	2003-07-10	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Immunoconjugates useful for treatment of tumours
BRPI0315666B8 (pt)	2002-10-23	2021-05-25	Ludwig Inst For Cancer Res Ltd	dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
EP1558645B1 (en)	2002-11-08	2011-07-27	Ablynx N.V.	Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
WO2004041863A2 (en)	2002-11-08	2004-05-21	Ablynx N.V.	Single domain antibodies directed against interferon- gamma and uses therefor
US9320792B2 (en)	2002-11-08	2016-04-26	Ablynx N.V.	Pulmonary administration of immunoglobulin single variable domains and constructs thereof
MXPA05007151A (es)	2002-12-31	2005-09-21	Nektar Therapeutics Al Corp	Polimeros terminados en maleimida hidroliticamente estables.
JP2006517789A (ja)	2003-01-10	2006-08-03	アブリンクスエン．ヴェー．	治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
US7461263B2 (en)	2003-01-23	2008-12-02	Unspam, Llc.	Method and apparatus for a non-revealing do-not-contact list system
DE602004017726D1 (de)	2003-06-30	2008-12-24	Domantis Ltd	Pegylierte Single-domain-antikörper (dAb)
EP1656128A4 (en)	2003-08-12	2007-02-28	William M Yarbrough	SINGLE ACNE TREATMENT AND METHOD OF USE
ATE485307T1 (de)	2003-11-07	2010-11-15	Ablynx Nv	Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
CA2548513A1 (en)	2003-12-04	2005-07-07	Wyeth	Biaryl sulfonamides and methods for using same
US7563443B2 (en)	2004-09-17	2009-07-21	Domantis Limited	Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006040153A2 (en)	2004-10-13	2006-04-20	Ablynx N.V.	Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
AU2005325801A1 (en)	2005-01-31	2006-08-03	Ablynx N.V.	Method for generating variable domain sequences of heavy chain antibodies
US8188223B2 (en)	2005-05-18	2012-05-29	Ablynx N.V.	Serum albumin binding proteins
ES2694247T3 (es)	2005-05-20	2018-12-19	Ablynx N.V.	NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
WO2008020079A1 (en)	2006-08-18	2008-02-21	Ablynx N.V.	Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
US20080267949A1 (en)	2006-12-05	2008-10-30	Ablynx N.V.	Peptides capable of binding to serum proteins
EP2102244A2 (en) *	2006-12-19	2009-09-23	Ablynx N.V.	Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
EP2121757A2 (en)	2007-02-21	2009-11-25	Ablynx N.V.	Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
CA2687903C (en)	2007-05-24	2016-09-13	Ablynx N.V.	Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
CA2712432C (en)	2008-01-29	2018-09-25	Ablynx N.V.	Methods to stabilize single variable domains
WO2009127691A1 (en)	2008-04-17	2009-10-22	Ablynx N.V.	Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US9265834B2 (en)	2009-03-05	2016-02-23	Ablynx N.V.	Stable formulations of polypeptides and uses thereof
NZ595461A (en)	2009-04-10	2013-01-25	Ablynx Nv	Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
AU2010243551B2 (en)	2009-04-30	2015-03-26	Ablynx Nv	Method for the production of domain antibodies
AU2010266272A1 (en) *	2009-07-02	2012-01-19	Glaxo Group Limited	Polypeptides and method of treatment
LT2805731T (lt)	2009-09-03	2019-02-11	Ablynx N.V.	Stabilios polipeptidų kompozicijos ir jų panaudojimas
DK2533761T3 (da)	2010-02-11	2019-06-24	Ablynx Nv	Fremgangsmåder og sammensætninger til fremstilling af aerosoler
WO2012152823A1 (en)	2011-05-09	2012-11-15	Ablynx Nv	Method for the production of immunoglobulin single variable domains
SG10201805064SA (en) *	2011-06-23	2018-07-30	Ablynx Nv	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
HUE031089T2 (en)	2012-04-13	2017-06-28	Rottapharm Biotech Srl	Anti-ADAMTS-5 antibody, derivatives and uses
ES2627281T3 (es) *	2013-02-06	2017-07-27	Merck Patent Gmbh	Derivados del ácido carboxílico sustituidos como agregados agrecanasa para el tratamiento de la artrosis
CN115160441A (zh)	2013-09-26	2022-10-11	埃博灵克斯股份有限公司	双特异性纳米抗体
PT3057992T (pt)	2013-10-15	2024-07-10	Univ Keio	Anticorpo humano contra espécies de adamts do tipo agrecanase para terapêuticas de doenças relacionadas com agrecanase
EP4707303A2 (en)	2014-05-16	2026-03-11	Ablynx NV	Improved immunoglobulin variable domains
EP3209794A1 (en)	2014-10-22	2017-08-30	Katholieke Universiteit Leuven KU Leuven Research & Development	Modulating adipose tissue and adipogenesis
AU2016214317B2 (en)	2015-02-05	2022-01-13	Ablynx N.V.	Nanobody dimers linked via C-terminally engineered cysteins
CN118894939A (zh)	2017-06-02	2024-11-05	默克专利股份有限公司	结合adamts的免疫球蛋白
JP7249961B2 (ja)	2017-06-02	2023-03-31	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	Ａｄａｍｔｓ５、ｍｍｐ１３およびアグリカンに結合するポリペプチド
IT201800003818A1 (it)	2018-03-21	2019-09-21	Fond Per Listituto Oncologico Di Ricerca Ior	Nuovi farmaci prosenescenza

2018
- 2018-06-04 CN CN202410787210.3A patent/CN118894939A/zh active Pending
- 2018-06-04 WO PCT/EP2018/064665 patent/WO2018220234A1/en not_active Ceased
- 2018-06-04 RS RS20241271A patent/RS66191B1/sr unknown
- 2018-06-04 HU HUE18730689A patent/HUE068952T2/hu unknown
- 2018-06-04 KR KR1020257000333A patent/KR20250011229A/ko active Pending
- 2018-06-04 TW TW107119218A patent/TWI802576B/zh active
- 2018-06-04 IL IL270908A patent/IL270908B1/en unknown
- 2018-06-04 CA CA3063293A patent/CA3063293A1/en active Pending
- 2018-06-04 HR HRP20241562TT patent/HRP20241562T1/hr unknown
- 2018-06-04 EP EP18730689.9A patent/EP3630847B1/en active Active
- 2018-06-04 BR BR112019024333-0A patent/BR112019024333A2/pt unknown
- 2018-06-04 DK DK18730689.9T patent/DK3630847T3/da active
- 2018-06-04 CN CN201880036462.5A patent/CN111032695B/zh active Active
- 2018-06-04 EP EP23184254.3A patent/EP4272822A3/en active Pending
- 2018-06-04 MX MX2019014400A patent/MX2019014400A/es unknown
- 2018-06-04 US US16/617,885 patent/US11261260B2/en active Active
- 2018-06-04 LT LTEPPCT/EP2018/064665T patent/LT3630847T/lt unknown
- 2018-06-04 KR KR1020197038469A patent/KR102752550B1/ko active Active
- 2018-06-04 SI SI201831176T patent/SI3630847T1/sl unknown
- 2018-06-04 JP JP2019566819A patent/JP7758459B2/ja active Active
- 2018-06-04 ES ES18730689T patent/ES3002733T3/es active Active
- 2018-06-04 AU AU2018277343A patent/AU2018277343B2/en active Active
- 2018-06-04 PL PL18730689.9T patent/PL3630847T3/pl unknown
- 2018-06-04 FI FIEP18730689.9T patent/FI3630847T3/fi active
- 2018-06-04 PT PT187306899T patent/PT3630847T/pt unknown
2022
- 2022-01-19 US US17/579,345 patent/US12209136B2/en active Active
2023
- 2023-05-30 JP JP2023088623A patent/JP2023123448A/ja active Pending
2024
- 2024-12-16 US US18/983,096 patent/US20250257145A1/en active Pending
2025
- 2025-04-04 AU AU2025202424A patent/AU2025202424A1/en active Pending

Also Published As

Publication number	Publication date
RU2019143075A (ru)	2021-07-13
AU2018277343B2 (en)	2025-01-23
RS66191B1 (sr)	2024-12-31
CN111032695B (zh)	2024-06-25
WO2018220234A1 (en)	2018-12-06
KR20250011229A (ko)	2025-01-21
TW201920287A (zh)	2019-06-01
TWI802576B (zh)	2023-05-21
AU2025202424A1 (en)	2025-04-24
EP3630847B1 (en)	2024-09-04
CN111032695A (zh)	2020-04-17
PL3630847T3 (pl)	2025-02-03
RU2019143075A3 (da)	2021-11-12
US20200317802A1 (en)	2020-10-08
HUE068952T2 (hu)	2025-02-28
IL270908B1 (en)	2026-04-01
EP4272822A2 (en)	2023-11-08
CN118894939A (zh)	2024-11-05
CA3063293A1 (en)	2018-12-06
MX2019014400A (es)	2020-02-10
US20250257145A1 (en)	2025-08-14
AU2018277343A1 (en)	2020-01-02
SI3630847T1 (sl)	2025-03-31
JP2020525410A (ja)	2020-08-27
BR112019024333A2 (pt)	2020-07-28
IL270908A (en)	2020-01-30
LT3630847T (lt)	2024-12-10
ES3002733T3 (en)	2025-03-07
FI3630847T3 (fi)	2024-12-05
EP4272822A3 (en)	2024-03-27
US12209136B2 (en)	2025-01-28
JP2023123448A (ja)	2023-09-05
US11261260B2 (en)	2022-03-01
JP7758459B2 (ja)	2025-10-22
HRP20241562T1 (hr)	2025-01-31
US20220289860A1 (en)	2022-09-15
PT3630847T (pt)	2024-11-21
KR102752550B1 (ko)	2025-01-10
EP3630847A1 (en)	2020-04-08
KR20200012935A (ko)	2020-02-05

Publication	Publication Date	Title
DK3731771T3 (da)	2023-08-28	V462033dk00
CL2018000524S1 (es)	2018-10-05	Golilla
EP3589248A4 (en)	2021-01-06	CRYOTHERAPIES
DE202018003363U8 (de)	2019-01-24	Handgelenkssphygmomanometer
EP3634404C0 (en)	2024-11-20	PYRAZOLE-BASED MAGL INHIBITORS
EP3588580A4 (en)	2020-12-02	SCHOTTKY MOS TRENCH DIODE
DK3351526T3 (da)	2021-02-08	Diisopentylterephthalat
EP3654852A4 (en)	2020-06-17	TOURNIQUET
EP3634397A4 (en)	2021-03-17	HETEROCYCLYL POLYMETHINE-BASED IR CHROMOPHORES
DK3568655T3 (da)	2023-04-17	Rekuperator
DK3571580T5 (da)	2021-11-08	Load-logical-and-shift-guarded-instruktion
DK3612237T3 (da)	2021-12-06	Genterapi
EP3611402A4 (en)	2020-04-15	SERVO CYLINDER
EP3615471A4 (en)	2021-01-06	PLASMA PHOTOELECTRONIC IMMUNE SENSOR
DK3630847T3 (da)	2024-12-02	Adamts-bindende immunglobuliner
EP3669219C0 (en)	2024-08-14	NETWORK SCALE
DK3576686T3 (da)	2022-01-03	Brokbind
DK3568506T3 (da)	2021-03-01	Offeranode
DK3510051T3 (da)	2020-03-16	Carboxylalkylchitosan
DK3676276T3 (da)	2022-02-21	Spirothietannukleosider
DK3395159T3 (da)	2020-02-24	Ballepresse
DK3576718T3 (da)	2021-08-23	Pastil
EP3618835A4 (en)	2021-03-17	APRAMYCIN DERIVATIVES
DK3391733T3 (da)	2020-03-16	Ballepresse
EP3575349A4 (en)	2020-02-19	RESIN FILM BASED ON VINYLIDENE FLUORIDE